Search results for " geriatric"

showing 10 items of 212 documents

Magnesium Status in Alzheimer's Disease: A Systematic Review

2016

The interest in poor magnesium (Mg) status as risk factor for Alzheimer's disease (AD) is increasing due to its antioxidant and neuroprotective properties. A systematic PubMed literature search of studies investigating Mg status was undertaken comparing AD to healthy controls (HCs) or patients with medical illness (medical controls [MCs]). Standardized mean differences (SMDs) ± 95% confidence intervals (CIs) were calculated for all outcomes. Of 192 potentially eligible studies, 13 were included (559 patients with AD, 381 HCs, and 126 MCs). Compared to HCs, patients with AD had significantly lower Mg in cerebrospinal fluid (2 studies; SMD = -0.35; P =.02) and in hair (2 studies; SMD = -0.75;…

0301 basic medicineAlzheimer’s disease; aging; dementia; healthy controls; magnesiummedicine.medical_specialtyDiseasemagnesiumbehavioral disciplines and activitiesnot knownNO03 medical and health sciences0302 clinical medicineAlzheimer DiseaseMedical illnessInternal medicinemedicineHumansDementiaRisk factorbusiness.industryGeneral NeuroscienceagingAlzheimer's diseasemedicine.diseaseConfidence intervalPsychiatry and Mental healthClinical Psychology030104 developmental biologyPhysical therapyhealthy controlsaging; Alzheimer's disease; dementia; healthy controls; magnesium; Psychiatry and Mental Health; Geriatrics and Gerontology; Clinical PsychologyGeriatrics and GerontologyAlzheimer's diseasebusinessAlzheimer’s disease030217 neurology & neurosurgerydementia
researchProduct

FGFR a promising druggable target in cancer: Molecular biology and new drugs.

2017

Abstract: Introduction: The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR. Areas Covered: This review summarizes the current status of treatments targeting FGFR, focusing on the trials that are evaluating the FGFR profile as inclusion criteria: Multi-Target, Pan-FGFR Inhibitors and anti-FGF (Fibroblast Growth Factor)/FGFR Monoclonal Antibodies. Expert opinion: Most of the TKR share …

0301 basic medicineFibroblast Growth FactorDruggabilityFibroblast growth factorTyrosine-kinase inhibitorReceptor tyrosine kinase0302 clinical medicineNeoplasmsFGFR inhibitorsFGFMolecular Targeted TherapyCancerCancer; FGF; FGFR; FGFR inhibitors; Drug Resistance Neoplasm; Fibroblast Growth Factors; Gene Fusion; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Protein Kinase Inhibitors; Receptors Fibroblast Growth Factor; Signal Transduction; Hematology; Oncology; Geriatrics and GerontologybiologyFGFRHematologyFGFR inhibitorOncologyFibroblast growth factor receptor030220 oncology & carcinogenesisembryonic structuresSignal transductionbiological phenomena cell phenomena and immunityGene FusionHumanSignal Transductionmusculoskeletal diseasesanimal structuresmedicine.drug_classProtein Kinase Inhibitor03 medical and health sciencesmedicineHumansProtein Kinase InhibitorsCancer; FGF; FGFR; FGFR inhibitorsbusiness.industryCancermedicine.diseaseMolecular biologyReceptors Fibroblast Growth FactorFibroblast Growth Factors030104 developmental biologyDrug Resistance NeoplasmCancer cellMutationbiology.proteinNeoplasmHuman medicineGeriatrics and GerontologybusinessCritical reviews in oncology/hematology
researchProduct

A multidimensional approach to frailty in older people

2020

Frailty is an important factor determining a higher risk of adverse health outcomes in older adults. Although scientific community in the last two decades put a lot of effort for its definition, to date no consensus was reached on its assessment. The mainstream thinking describes frailty as a loss of physical functions or as accumulation of multiple deficits. Recently, a novel conceptual model of frailty has emerged based on the loss of harmonic interaction between multiple domains (also referred as dimensions) including genetic, biological, functional, cognitive, psychological and socio-economic domain that ultimately lead to homeostatic instability. Therefore, the multidimensional aspects…

0301 basic medicineGerontologyAgingInstitutionalisationFrail Elderlymedia_common.quotation_subjectFrail Older AdultsPopulationComprehensive geriatric assessmentHealth outcomesBiochemistryArticle03 medical and health sciences0302 clinical medicineMultidimensional prognostic indexHumanseducationGeriatric AssessmentMolecular BiologyAgedmedia_commonAged 80 and overeducation.field_of_studyFrailtyGeriatric assessmentCognitionPrognosis030104 developmental biologyNeurologyConceptual modelPsychologyOlder people030217 neurology & neurosurgeryBiotechnologyAgeing Research Reviews
researchProduct

Multidimensional frailty increases cardiovascular risk in older people: An 8-year longitudinal cohort study in the Osteoarthritis Initiative.

2021

Background:\ud \ud Cardiovascular diseases (CVDs) are the most important cause of mortality and an important cause of disability. Frailty seems to be associated with higher cardiovascular risk, but limited research has been done using a multidimensional approach to frailty. Thus, the present study aimed to investigate whether the multidimensional prognostic index (MPI), based on comprehensive geriatric assessment (CGA), is associated with CVD risk in the Osteoarthritis Initiative (OAI) study.\ud \ud Methods:\ud \ud Community-dwellers affected by knee OA or at high risk for this condition were followed for 8 years. A standardized CGA including information on functional, nutritional, mood, co…

0301 basic medicineGerontologyAgingOsteoarthritisComprehensive geriatric assessmentLogistic regressionBiochemistryCohort Studies03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeRisk FactorsMultidimensional prognostic indexOsteoarthritisGeneticsRisk of mortalityMedicineHumansLongitudinal StudiesLongitudinal cohortMolecular BiologyGeriatric AssessmentAgedFrailtybusiness.industryConfoundingCell BiologyCardiovascular diseaseCardiovascular riskmedicine.diseasePrognosis030104 developmental biologyMoodOsteoarthritis InitiativeCardiovascular DiseasesHeart Disease Risk FactorsQuality of LifeFemalebusinessOlder people030217 neurology & neurosurgeryExperimental gerontology
researchProduct

The prevalence of malnutrition according to the new ESPEN definition in four diverse populations

2016

© 2015 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism.Background & aims: Consensus on the definition of malnutrition has not yet been reached. Recently, The European Society for Clinical Nutrition and Metabolism (ESPEN) proposed a consensus definition of malnutrition. The aim of the present study was to describe the prevalence of malnutrition according to the ESPEN definition in four diverse populations. Methods: In total, 349 acutely ill middle-aged patients, 135 geriatric outpatients, 306 healthy old individuals and 179 healthy young individuals were included in the study. Subjects were screened for risk of malnutrition using the SNAQ. The ESPEN definition of maln…

0301 basic medicineGerontologyMalePediatricsNutritional SciencesCritical Care and Intensive Care MedicineThinness/etiologygeriatric patientBody Mass IndexNutritional Sciences/methods0302 clinical medicineunderweightWeight loss/dk/atira/pure/sustainabledevelopmentgoals/zero_hungerPrevalenceMedicine030212 general & internal medicineYoung adultcomparative studypathophysiologyhealth care organizationNutrition and Dieteticsta3141Scientificta3142Middle AgedEuropenutritional assessmentElder Nutritional Physiological PhenomenaoutpatientAcute DiseasePractice Guidelines as TopicBody CompositionFemalemedicine.symptomRisk assessmentSocieties ScientificPredictive validityAdultRiskmedicine.medical_specialtyConsensusgeriatric nutritionNutritional Statusmalnutritionadult; aged; Article; body mass; controlled study; disease predisposition; fat free mass; female; geriatric patient; human; major clinical study; male; malnutrition; middle aged; nutritional assessment; outpatient; population research; predictive validity; prevalence; risk assessment; short nutritional assessment questionnaire; weight reduction; acute disease; body composition; comparative study; consensus; Europe; geriatric assessment; geriatric nutrition; health care organization; malnutrition; nutritional assessment; nutritional science; nutritional status; pathophysiology; practice guideline; procedures; risk; risk assessment; underweight; young adult Acute Disease; Adult; Aged; Body Composition; Body Mass Index; Consensus; Elder Nutritional Physiological Phenomena; Europe; Female; Geriatric Assessment; Humans; Male; Malnutrition; Middle Aged; Nutrition Assessment; Nutritional Sciences; Nutritional Status; Practice Guidelines as Topic; Prevalence; Risk; Risk Assessment; Societies Scientific; Thinness; Young Adult; Body mass index; Definition; Fat free mass index; Malnutrition; PrevalenceRisk AssessmentArticleEurope/epidemiology03 medical and health sciencesYoung AdultThinnessFat free mass indexHumanscontrolled studyhumanproceduresSDG 2 - Zero HungerGeriatric AssessmentAged030109 nutrition & dieteticsbusiness.industrypractice guidelinedisease predispositionDefinitionNUTRITION&DIETETICSmedicine.diseasemajor clinical studybody masspredictive validityMalnutritionNutrition Assessmentfat free massweight reductionshort nutritional assessment questionnairenutritional scienceNutritional sciencebusinessSocietiespopulation researchBody mass indexMalnutrition/diagnosisClinical Nutrition
researchProduct

Mild behavioral impairment in Parkinson's disease: Data from the Parkinson's disease cognitive impairment study (PACOS)

2019

Neuropsychiatric symptoms (NPS) have been frequently described in Parkinson's disease (PD), even in the earliest stages of the disease. Recently the construct of mild behavioral impairment (MBI) has been proposed as an at-risk state for incident cognitive decline and dementia. The aim of the present study is to evaluate the prevalence and associated factors of MBI in PD. Cross-sectional data from 429 consecutive PD patients enrolled in the PArkinson's disease COgnitive impairment Study (PACOS) were included in the study. All subjects underwent neuropsychological assessment, according to the MDS Level II criteria. NPS were evaluated with the Neuropsychiatric Inventory. Multivariate logistic …

0301 basic medicineMalemedicine.medical_specialtyParkinson's diseaseParkinson's diseaseMild behavioral impairmentNeuropsychiatric symptomDiseaseCognitive impairment; Mild behavioral impairment; Neuropsychiatric symptoms; Parkinson's disease; Prevalence; Neuroscience (all); Clinical Psychology; Geriatrics and Gerontology; Psychiatry and Mental HealthNeuropsychological TestsLogistic regressionSeverity of Illness Index03 medical and health sciences0302 clinical medicineInternal medicinemedicinePrevalenceDementiaHumansCognitive DysfunctionNeuropsychological assessmentCognitive declineStage (cooking)Cognitive impairmentAgedNeuroscience (all)medicine.diagnostic_testbusiness.industryGeneral NeuroscienceParkinson DiseaseGeneral MedicineMiddle Agedmedicine.diseaseNeuropsychiatric symptomsClinical Psychology030104 developmental biologyCross-Sectional StudiesCognitive impairmentPsychiatry and Mental HealthFemaleGeriatrics and Gerontologybusiness030217 neurology & neurosurgery
researchProduct

Effects of acetyl-l-carnitine in diabetic neuropathy and other geriatric disorders

2018

A long history of diabetes mellitus and increasing age are associated with the onset of diabetic neuropathy, a painful and highly disabling complication with a prevalence peaking at 50% among elderly diabetic patients. Acetyl-l-carnitine (ALC) is a molecule derived from the acetylation of carnitine in the mitochondria that has an essential role in energy production. It has recently been proposed as a therapy to improve the symptoms of diabetic neuropathy. ALC is widely distributed in mammalian tissues, including the brain, blood–brain barrier, brain neurons, and astrocytes. Aside from its metabolic activity, ALC has demonstrated cytoprotective, antioxidant, and antiapoptotic effects in the …

0301 basic medicineNervous systemAgingmedicine.medical_specialtyDiabetic neuropathyDiabetic neuropathyPainNeurotrophic effectAcetyl-l-carnitine; Analgesia; Diabetic neuropathy; Neurotrophic effect; Aging; Geriatrics and GerontologyNO03 medical and health sciences0302 clinical medicineDiabetic NeuropathiesAlzheimer DiseaseInternal medicineDiabetes mellitusmedicineHumansCarnitineAcetyl-l-carnitine; Analgesia; Diabetic neuropathy; Neurotrophic effectAcetylcarnitineAcetyl-l-carnitine Diabetic neuropathy Analgesia Neurotrophic effectAgedAnalgesicsbusiness.industryGlutamate receptormedicine.diseaseMitochondriaAcetyl-l-carnitine030104 developmental biologyNerve growth factorEndocrinologymedicine.anatomical_structureAnalgesiaGeriatrics and GerontologyAlzheimer's diseaseAcetylcarnitinebusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

EGFR inhibition in NSCLC: New findings…. and opened questions?

2017

The targeted inhibition of epidermal growth factor receptor (EGFR) has represented a milestone in the treatment of lung cancer. Several studies convincingly and consistently demonstrated a significant superiority of EGFR-TKIs over standard platinum-chemotherapy in EGFR-mutated NSCLC patients, leading to the sequential approval of gefitinib, erlotinib and afatinib as new standard first-line clinical treatment. To date we are witnessing a second revolution in the management of EGFR-positive NSCLC thanks to the development of new treatment strategies aiming to overcome acquired resistance to TKIs and ultimately improve patients’ outcomes. In this review we summarize the most important recent f…

0301 basic medicineOncologyLung Neoplasmsmedicine.medical_treatmentAfatinibResistanceTreatment of lung cancerTargeted therapyTargeted therapyAntineoplastic Agent0302 clinical medicineEpidermal growth factorEpidermal growth factor receptorMolecular Targeted TherapybiologyHematologyTKIErbB ReceptorsOncology030220 oncology & carcinogenesisErlotinibReceptorHumanmedicine.drugmedicine.medical_specialtyEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEGFRProtein Kinase InhibitorAntineoplastic Agents03 medical and health sciencesGefitinibInternal medicinemedicineHumansLiquid biopsyIntensive care medicineProtein Kinase InhibitorsEGFR; Liquid biopsy; Resistance; Targeted therapy; TKIs; Antineoplastic Agents; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Receptor; Epidermal Growth Factor; Hematology; Oncology; Geriatrics and GerontologyEpidermal Growth FactorLiquid biopsybusiness.industryrespiratory tract diseasesLung Neoplasm030104 developmental biologyTKIsMutationbiology.proteinReceptor Epidermal Growth FactorGeriatrics and Gerontologybusiness
researchProduct

Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis.

2016

Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metastases (CLM), showing conflicting results. This meta-analysis aims to review all the studies reporting survival outcomes (recurrence free survival (RFS), and/or overall survival (OS)) of patients undergoing resection of CLM, stratified according to KRAS and/or BRAF mutation status. Background: Clinical trials investigated the potential role of both KRAS and BRAF mutations, as prognostic biomarkers, in colorectal cancer (CRC) patients who underwent surgical treatment of CRC-related liver metast…

0301 basic medicineOncologyendocrine system diseasesColorectal cancerLiver metastasimedicine.medical_treatmentColorectal Neoplasmmedicine.disease_cause0302 clinical medicineLiver metastasisHematologyTumorLiver NeoplasmsHematologyPrognosisSurvival RateOncologyLiver Neoplasm030220 oncology & carcinogenesisMeta-analysisKRASColorectal NeoplasmsHumanProto-Oncogene Proteins B-rafmedicine.medical_specialtyPrognostic biomarkerPrognosiResectionBRAFProto-Oncogene Proteins p21(ras)03 medical and health sciencesInternal medicineBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologymedicineKRASBiomarkers TumorHepatectomyHumansneoplasmsSurvival ratebusiness.industrymedicine.diseaseColorectal cancerdigestive system diseasesClinical trial030104 developmental biologyMutationBRAF; Colorectal cancer; KRAS; Liver metastasis; Prognostic biomarker; Biomarkers; Tumor; Colorectal Neoplasms; Humans; Liver Neoplasms; Mutation; Prognosis; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Survival Rate; Hepatectomy; Oncology; Hematology; Geriatrics and GerontologyHepatectomyGeriatrics and GerontologybusinessBiomarkersCritical reviews in oncology/hematology
researchProduct

Factors influencing serum 25-hydroxivitamin D levels and other bone metabolism parameters in healthy older women

2016

Objective: Older women have frequently low serum 25-hydroxivitamin D (25[OH]D) concentrations, high parathormone (PTH) levels and low bone mineral density (BMD) values. Endogenous synthesis, dietary habits, sunlight exposure and fat-mass-mediated storage may influence 25(OH)D levels and bone metabolism, but the relevance of these factors in the elderly has yet to be fully elucidated. We aimed to investigate the influence of dietary vitamin D intake and fat mass on serum 25(OH)D levels and bone metabolism in older women. Design: Cross-sectional. Setting: Community. Participants: 218 fit older women attending a biweekly mild fitness program. Measurements: Dietary habits was investigated throu…

0301 basic medicinemedicine.medical_specialtyBone densityMedicine (miscellaneous)030209 endocrinology & metabolism25-hydroxyvitamin D; bone metabolism; dietary vitamin D intake; elderly; fat mass; Medicine (miscellaneous); Nutrition and Dietetics; Geriatrics and Gerontologydietary vitamin D intakeelderlyNOBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineVitamin D and neurologyFemoral neckBone mineralHyperparathyroidism030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryfat massmedicine.disease25-hydroxyvitamin Dmedicine.anatomical_structureEndocrinologychemistry25-hydroxyvitamin D dietary vitamin D intake fat mass bone metabolism elderlyCalcifediolSecondary hyperparathyroidismbone metabolismGeriatrics and GerontologybusinessThe journal of nutrition, health & aging
researchProduct